Ngen, Inc., formerly Nanogen, Inc., is a diagnostics company with the mission to make the detection, the diagnosis, and the treatment and monitoring of an individual’s health easier and faster. It participates in two markets. The first is the molecular diagnostics market where it offers assays for real-time polymerase chain reaction (PCR) applications. Molecular diagnostics is the analysis of deoxyribonucleic acid (DNA), ribonucleic acid and proteins at the molecular level and is performed in clinical laboratories. The second is the point-of-care (POC) market where it offers rapid immunoassay tests for cardiac emergency care. In POC, the diagnostic may be performed in near patient settings, such as an emergency room or doctor’s office. Within these two markets, the Company focuses primarily on infectious disease and cardiac testing. In May 2009, it filed a voluntary petition under chapter 11 of title 11 of the United States Code in the Bankruptcy Court for the District of Delaware.